Skip to main content
. 2024 Aug 28;598:217106. doi: 10.1016/j.canlet.2024.217106

Fig. 1.

Fig. 1

Drug sensitive screening using a panel of kinases inhibitors on IPDOs and DPDOs. (a) Flow chart of drug screening for kinases inhibitors in PDOs of GC. (b) A panel of kinases inhibitors, CAS number, and cell vitality of PDOs are presented. (c) The GSVA pathway analysis for IPDOs and DPDOs. (d) The heatmap shows sensitivity difference between IPDOs and DPDOs to kinases inhibitors. The color column on the right side represents drug sensitivity. The red indicates sensitivity and the blue indicates resistance. (e) The bar chart shows cell vitality difference to Barasertib-HQPA between IPDOs and DPDOs (**P = 0.0013). (f) The bar chart shows cell vitality difference to Danusertib between IPDOs and DPDOs (**P = 0.0018). (g) The transcriptomic levels of AURKB gene in IPDOs and DPDOs (**P = 0.002). (h) The correlation analysis of AURKB level and cell vitality upon Barasertib-HQPA treatment (r = −0.7658). (i) The correlation analysis of AURKB level and cell vitality upon Danusertib treatment (r = −0.6185).